Dexcom Recalls Receivers Due to Critical Safety Issue, as Innovations in CGM Surge
Dexcom has issued a Class 1 recall for several of its receivers due to a critical patient safety issue. The malfunction could lead to dangerously high or low blood sugar levels. Meanwhile, innovations in continuous glucose monitoring (CGM) technologies are on the rise, with companies investing in AI and advanced sensors to improve glucose monitoring and prevent complications.
The recall affects Dexcom G6, G7, ONE, and ONE+ receivers, with around 56 cases of severe symptoms reported, including seizures, loss of consciousness, and hypoglycemic or hyperglycemic episodes. The issue stems from a speaker malfunction that can fail to alert users to critical glucose levels.
Innovations in CGM technologies are addressing these challenges. Percusense has proposed a patent-pending device that monitors multiple biomarkers, such as lactate, oxygen, and ketones, to predict blood sugar changes and prevent risks like hypoglycemia. Abbott is developing a CGM system that can measure and analyze lactate in addition to glucose. Huawei has launched a wearable device using photoplethysmography (PPG) signals for non-invasive blood glucose monitoring. Dual AI is creating an AI-powered health system that combines CGM with personalized food and activity tracking to predict and prevent food-induced blood sugar spikes.
These advancements come as healthcare giants and startups invest heavily in AI integration, automated algorithms, and advanced sensor technologies to improve glucose monitoring. The need for preventive and affordable glucose monitoring technologies is urgent, as diabetes and related complications consume nearly 20% of the Gross Domestic Product (GDP).
Dexcom's recall underscores the importance of reliable CGM technologies. As the industry responds with innovative solutions, our website can help track new developments, identify collaboration and acquisition opportunities, and refine existing products for R&D teams. These advancements aim to improve the lives of people with diabetes and reduce the economic burden of the disease.
